- Home
- BVN vs SYRE Comparison
BVN vs SYRE Comparison
Compare BVN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVN | SYRE |
|---|---|---|
| Founded | 1953 | 2013 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.6B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BVN | SYRE |
|---|---|---|
| Price | $31.93 | $82.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 18 |
| Target Price | $38.53 | ★ $119.93 |
| AVG Volume (30 Days) | 983.1K | ★ 1.4M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.00 | $21.01 |
| 52 Week High | $44.67 | $110.18 |
Technical Indicators
Market Signals| Indicator | BVN | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 41.34 |
| Support Level | $29.51 | $66.78 |
| Resistance Level | $32.80 | $94.10 |
| Average True Range (ATR) | 0.93 | 4.63 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 55.78 | 30.85 |
Price Performance
Historical ComparisonAbout BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.